AU2001277524A1 - Novel use of inhibitors of the epidermal growth factor receptor - Google Patents
Novel use of inhibitors of the epidermal growth factor receptorInfo
- Publication number
- AU2001277524A1 AU2001277524A1 AU2001277524A AU7752401A AU2001277524A1 AU 2001277524 A1 AU2001277524 A1 AU 2001277524A1 AU 2001277524 A AU2001277524 A AU 2001277524A AU 7752401 A AU7752401 A AU 7752401A AU 2001277524 A1 AU2001277524 A1 AU 2001277524A1
- Authority
- AU
- Australia
- Prior art keywords
- inhibitors
- growth factor
- factor receptor
- epidermal growth
- novel use
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00114482 | 2000-07-06 | ||
EP00114482A EP1170011A1 (en) | 2000-07-06 | 2000-07-06 | Novel use of inhibitors of the epidermal growth factor receptor |
PCT/EP2001/007642 WO2002002120A1 (en) | 2000-07-06 | 2001-07-04 | Novel use of inhibitors of the epidermal growth factor receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001277524A1 true AU2001277524A1 (en) | 2002-01-14 |
Family
ID=8169176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001277524A Abandoned AU2001277524A1 (en) | 2000-07-06 | 2001-07-04 | Novel use of inhibitors of the epidermal growth factor receptor |
Country Status (4)
Country | Link |
---|---|
US (1) | US20020102685A1 (en) |
EP (1) | EP1170011A1 (en) |
AU (1) | AU2001277524A1 (en) |
WO (1) | WO2002002120A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
CZ200438A3 (en) | 2001-06-13 | 2004-06-16 | Genmab A/S | The title is not available |
EP1300146A1 (en) * | 2001-10-03 | 2003-04-09 | Boehringer Ingelheim International GmbH | Pharmaceutical composition for the treatment of animal mammary tumors |
DE10154540A1 (en) * | 2001-11-07 | 2003-05-22 | Cellcontrol Biomedical Lab Ag | Procedure for predicting or predicting the effectiveness of tumor treatment |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US20040147428A1 (en) * | 2002-11-15 | 2004-07-29 | Pluenneke John D. | Methods of treatment using an inhibitor of epidermal growth factor receptor |
US8017321B2 (en) * | 2004-01-23 | 2011-09-13 | The Regents Of The University Of Colorado, A Body Corporate | Gefitinib sensitivity-related gene expression and products and methods related thereto |
US20080090233A1 (en) * | 2004-05-27 | 2008-04-17 | The Regents Of The University Of Colorado | Methods for Prediction of Clinical Outcome to Epidermal Growth Factor Receptor Inhibitors by Cancer Patients |
AU2005250484B2 (en) | 2004-06-04 | 2011-08-11 | Genentech, Inc. | EGFR mutations |
WO2006017317A2 (en) * | 2004-07-12 | 2006-02-16 | The General Hospital Corporation | Method for the treatment of disease |
US20060134064A1 (en) * | 2004-12-20 | 2006-06-22 | David Goldstein | Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor |
EP1861094A4 (en) * | 2005-03-11 | 2014-06-11 | Univ Colorado | Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
JP2008546421A (en) * | 2005-06-28 | 2008-12-25 | ジェネンテック・インコーポレーテッド | EGFR and KRAS mutations |
EP2041389B1 (en) | 2006-06-09 | 2010-08-11 | University Court Of The University Of Aberdeen | Resonance enhanced drilling: method and apparatus |
JP2010509370A (en) * | 2006-11-10 | 2010-03-25 | シンダックス ファーマシューティカルズ,インク. | Combination of ERα + ligand and histone deacetylase inhibitor for the treatment of cancer |
US20090131367A1 (en) * | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
DE69536015D1 (en) * | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Quinazolinone derivatives |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
BR9609617B1 (en) * | 1995-07-06 | 2010-07-27 | 7h-pyrrol [2,3-d] pyrimidine derivatives, and pharmaceutical composition. | |
DE19608588A1 (en) * | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and processes for their preparation |
GB9608180D0 (en) * | 1996-04-19 | 1996-06-26 | Cancer Res Campaign Tech | Phosphate analogues |
NZ512189A (en) * | 1998-11-19 | 2003-10-31 | Warner Lambert Co | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4- yl-propoxy)-quinazolin-6-yl]-acrylamide useful as an irreversible inhibitor of tyrosine kinases |
CZ20012910A3 (en) * | 1999-02-11 | 2002-02-13 | Pfizer Products Inc. | Heteroaryl-substituted quinolin-2-one derivatives usable as antitumor preparations |
-
2000
- 2000-07-06 EP EP00114482A patent/EP1170011A1/en not_active Withdrawn
-
2001
- 2001-07-04 WO PCT/EP2001/007642 patent/WO2002002120A1/en active Application Filing
- 2001-07-04 AU AU2001277524A patent/AU2001277524A1/en not_active Abandoned
- 2001-07-06 US US09/899,571 patent/US20020102685A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002002120A1 (en) | 2002-01-10 |
EP1170011A1 (en) | 2002-01-09 |
US20020102685A1 (en) | 2002-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002227435A1 (en) | Antisense modulation of calreticulin expression | |
AU2001237041A1 (en) | Kinase inhibitors | |
AU2001258771A1 (en) | -secretase inhibitors | |
AU6421101A (en) | Surgical clip | |
AU2001234128A1 (en) | Novel imidazoline compounds | |
AU2001229712A1 (en) | Reduction of hair growth | |
AU2437900A (en) | Piperidinylquinolines as protein tyrosine kinase inhibitors | |
GB0025782D0 (en) | Use of inhibitors | |
AU2001244355A1 (en) | Heterobiarylsulphonamides and their use as pde 7 inhibitors | |
AU2001270260A1 (en) | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | |
AU2001277524A1 (en) | Novel use of inhibitors of the epidermal growth factor receptor | |
AU2002224808A1 (en) | Use of thienopyrimidines | |
AU2576501A (en) | Protein kinase inhibitors | |
AU2002217071A1 (en) | Novel use of polyhydroxy compounds | |
AU2001276027A1 (en) | Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors | |
AU7961300A (en) | Kainic acid neurocytotoxicity inhibitors | |
AU2001239246A1 (en) | Novel use of herbicides | |
AU2002338734A1 (en) | Use of phosphorodiesterase IV inhibitors | |
AU3235100A (en) | Prothease inhibitors | |
AU2001249074A1 (en) | Human hepatocyte growth factor activator inhibitor homologue | |
AU7445100A (en) | Sebum production inhibitors | |
AU5587200A (en) | Synthesis of substituted amidines | |
AU3595900A (en) | Tyrosine alkoxyguanidines as integrin inhibitors | |
AU4450100A (en) | 225Ac-heha and related compounds, methods of synthesis and methods of use | |
AU4021700A (en) | Methods of use of beta1-integrin inhibitors |